Summer 2004

Page 1

THE BURNHAM INSTITUTE

IN THIS ISSUE:

> Anti-obesity

> Genetic

drug inhibits prostate cancer growth

FROM RESEARCH,

research may improve heart function

> NIH-sponsored stem cell course held at Burnham

THE POWER TO CURE.

The Burnham Report SUMMER 2004

Vol. 2, No. 1

new treatments underway for prostate cancer. Potential

Prostate cancer growth can be slowed by a commonly prescribed anti-obesity drug, according to recent work by Burnham Associate Professor Jeffrey Smith and his research team. The investigators showed that the drug, orlistat (marketed by Roche as XENICAL™), inhibits prostate tumor growth in mice without any apparent side effects.

Welcome to the third issue of The Burnham Report. In this issue, you’ll read about the discovery that a commonly prescribed obesity drug may have efficacy against prostate cancer, a finding that opens the door to identifying new drugs with even more potency. You’ll learn about a growing research area at Burnham—investigations relevant to heart disease.Two of our newest faculty members round out our research team in this field. The issue of stem cell research is heating up, as Californians prepare to vote this fall on an initiative to provide state funds to support research not eligible for federal funds under current guidelines.The Burnham Institute has come forward in support of this initiative. Inside you’ll also read about our involvement in one of only five NIH-sponsored courses in human embryonic stem cell biology, held recently at Burnham and co-sponsored by Children’s Hospital Orange County. All of us at The Burnham Institute are grateful for your interest and support of our research.

“This is a big advance in the sense that

Additional screening of breast cancer

we have an approved drug—approved

and colon cancer cells revealed that

for one indication—that has another

fatty acid synthase activity is highly

target and another potential disease

active in these tumors as well, indicat-

indication, prostate cancer,” says Smith.

ing they may also be susceptible to

Tumor cells require enormous

orlistat or a similar drug. Orlistat was

amounts of energy to fuel their unbri-

originally developed to inhibit an

dled growth and division. Orlistat

enzyme that processes fats in the

works to cut off this energy supply by

digestive tract, thereby preventing

disabling an enzyme that plays a key

absorption of dietary fat.

role in metabolism, the production of

The screening method developed

energy from food. Smith and his col-

and used by Smith in this study repre-

leagues developed a chemical screen

sents a quantum leap in drug discovery.

that showed that prostate cancer cells

It allows investigators to compile

have unusually high levels of the

a comprehensive profile of a drug or

enzyme fatty acid synthase, which con-

potential drug’s activities, revealing

verts dietary carbohydrate to fat. The

unintended functions. Smith now

same screen also identified orlistat’s

plans to work on synthesis and testing

ability to block the enzyme. The results

of derivatives of orlistat to increase

were published in the March 15th edi-

the effectiveness of the drug’s action

tion of the journal Cancer Research.

toward tumors.

JOHN C. REED, M.D., PH.D.

President and CEO

Jeffrey Smith, Ph.D. Associate Professor, Cancer Center


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.